Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet.
Publication
, Journal Article
Vincenti, F; Budde, K; Grinyo, J; Rostaing, L; Kirk, AD; Larsen, CP
Published in: Am J Transplant
October 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Transplant
DOI
EISSN
1600-6143
Publication Date
October 2023
Volume
23
Issue
10
Start / End Page
1483 / 1484
Location
United States
Related Subject Headings
- Surgery
- Kidney Transplantation
- Immunosuppressive Agents
- Abatacept
- 3204 Immunology
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Vincenti, F., Budde, K., Grinyo, J., Rostaing, L., Kirk, A. D., & Larsen, C. P. (2023). Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet. Am J Transplant, 23(10), 1483–1484. https://doi.org/10.1016/j.ajt.2023.05.033
Vincenti, Flavio, Klemens Budde, Josep Grinyo, Lionel Rostaing, Allan D. Kirk, and Christian P. Larsen. “Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet.” Am J Transplant 23, no. 10 (October 2023): 1483–84. https://doi.org/10.1016/j.ajt.2023.05.033.
Vincenti F, Budde K, Grinyo J, Rostaing L, Kirk AD, Larsen CP. Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet. Am J Transplant. 2023 Oct;23(10):1483–4.
Vincenti, Flavio, et al. “Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet.” Am J Transplant, vol. 23, no. 10, Oct. 2023, pp. 1483–84. Pubmed, doi:10.1016/j.ajt.2023.05.033.
Vincenti F, Budde K, Grinyo J, Rostaing L, Kirk AD, Larsen CP. Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet. Am J Transplant. 2023 Oct;23(10):1483–1484.
Published In
Am J Transplant
DOI
EISSN
1600-6143
Publication Date
October 2023
Volume
23
Issue
10
Start / End Page
1483 / 1484
Location
United States
Related Subject Headings
- Surgery
- Kidney Transplantation
- Immunosuppressive Agents
- Abatacept
- 3204 Immunology
- 3202 Clinical sciences
- 11 Medical and Health Sciences